LIVN · earnings call history
LivaNova Q2 FY26 — Record Revenue & EPS Driven by CP and Epilepsy Strength
Read the briefLivaNova Q1 FY26 — Strong Revenue Growth Across Segments Driven by Essenz and Epilepsy Reimbursement
Read the briefLivaNova Q4 FY25 — Double-Digit Growth and Strategic Advancements
Read the briefBrowse all US companies on the earnings-call register.